Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bigfoot Biomedical Secures $57M In New Funding To Support Commercialization Of Diabetes Management System

Executive Summary

As Bigfoot awaits FDA clearance for its Bigfoot Unity System, the diabetes treatment company’s business model calls for packing the System as part of a one-stop-shop monthly subscription model.

You may also be interested in...



Bigfoot Biomedical Closes $55M Series C Financing, Plans FDA Filing For Diabetes System

Diabetes-care company Bigfoot Biomedical announced it raised $55m in a Series C round to support US FDA submission for its insulin delivery system.

Tandem Wins FDA Clearance On First Stand-Alone Glycemic Controller

Tandem Diabetes Care received FDA clearance for its Control-IQ technology for use with Tandem's t:slim X2 insulin pump and Dexcom's G6 continuous glucose monitoring system, making it the first hybrid closed-loop system to deliver automatic correction boluses and adjust background insulin levels to help prevent high and low blood sugars.

Surgical Robotics Company Vicarious Surgical To Merge With D8 SPAC In $1.1Bn Deal

Vicarious Surgical, whose medical robot received US FDA breakthrough designation, announced it will merge with D8 Holdings Corp. The deal is expected to garner up to $460m.

Topics

Related Companies

UsernamePublicRestriction

Register

MT143670

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel